Partner
Join the 3rd Liquid Biopsy Surveillance Summit for an unparalleled opportunity to network with over 150 key decision-makers driving the future of liquid biopsies in personalized medicine.
At this year's summit, you'll have the chance to showcase your cutting-edge tools, technologies, or expert services to a specialized community dedicated to advancing Minimal Residual Disease (MRD) detection, and surveillance assays. With the field continuing its rapid expansion into 2024, this is the perfect platform to position your solutions at the forefront of industry innovation.
Biopharma companies are actively seeking to collaborate on the latest advancements in non-invasive testing, eager to partner with those offering expertise in:
Liquid Biopsy Assay Development
Contract Research Organizations
Reference Laboratories
Next-Generation Sequencing (NGS) & Sequencing Providers for Diagnostics
Artificial Intelligence (AI)
Our 2024 Confirmed Partners:
Why Partner?
Forge Strategic Alliances: Accelerate your liquid biopsy projects through unmatched networking opportunities. Highlight your MRD detection and ctDNA analysis innovations to key partners shaping the future of oncology.
Â
Maximize Visibility: With top service providers securing partnerships, don’t just attend—stand out! Explore our sponsorship packages to ensure your brand is seen by the right audience.
Gain Cutting-Edge Insights: Stay ahead in precision medicine – and of your competitors - by engaging in sessions on breakthrough techniques for drug response monitoring, biomarker discovery, and transformative MRD detection.